To avoid system errors, if Chrome is your preferred browser, please update to the latest version of Chrome (81 or higher) or use an alternative browser.
Click here to login if you're an NAE Member
Recover Your Account Information
Dr. George Poste is the Del E. Webb Professor of Health Innovation and Chief Scientist, The Complex Adaptive Systems Initiative (CASI) at Arizona State University (ASU). This program integrates research in genomics, synthetic biology and high performance computing to study the altered regulation of molecular networks in human diseases to develop new diagnostic tests for precision medicine and the remote monitoring of health status using miniaturized body sensors and mobile devices. He assumed this post in 2009. From 2003 to 2009 he directed and built The Biodesign Institute at ASU.
He has published more than 350 research papers and edited 14 books on pharmaceutical technologies, cancer and infectious diseases. He has received honorary degrees in science, law and medicine for his contributions to research and international security.
He currently serves on the Board of Directors of Exelixis, Caris Life Sciences, and the Scientific Advisory Boards of the A. Alfred Taubman Medical Research Institute at the University of Michigan, Synthetic Genomics, Vir Biotechnology, iNanoBio, Haplogen GmbH (Vienna) and MediSix (Singapore).
From 1992 to 1999, he was Chief Science and Technology Officer and President, R&D, of SmithKline Beecham (SB) (now GlaxoSmithKilne). During his tenure at SB, he was associated with the successful registration of multiple drug, vaccine and diagnostic products. He has served on the Board of Directors of Structural Genomix (acquired by Lilly), Orchid Biosciences (acquired by LapCorp), diaDexus (acquired by Vaxgen), Monsanto (acquired by Bayer) and Advanced PCS (acquired by CVS-Caremark).
In 2004 he was named “R&D Scientist of the Year” by R&D Magazine, he received the Einstein award from the Global Business Leadership Council (2006), the Scrip Lifetime Achievement award voted by the leadership of the global pharmaceutical industry (2009) and the Arizona Bioindustry Association Pioneer Award (2016).
He is a Fellow of the U.K. Royal Society, the Royal College of Pathologists and the U.K. Academy of Medicine, a member of EU Academy of Sciences, the Council for Foreign Relations and the US Academy of Medicine Forum on Global Health. He served as a member of the Defense Science Board of the U.S. Department of Defense (2000 – 2009) and currently serves on advisory committees for several U.S. government agencies in defense, intelligence, national security and healthcare.